Drug profile · INN
tadalafil
ADCIRCA
tadalafil (ADCIRCA) is a phosphodiesterase 5a inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — tadalafil
- US status
- approved
- Class
- Genito-urinary system and sex hormones (G04)
- Route
- ORAL
- Patents
- 1
- Programs
- 11
- Data quality
- 0.89
Quick answer
tadalafil (ADCIRCA) is a phosphodiesterase 5a inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphodiesterase 5A inhibitor
Primary target: cGMP-specific 3',5'-cyclic phosphodiesterase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is tadalafil?
tadalafil (ADCIRCA) is a phosphodiesterase 5a inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tadalafil?
ADCIRCA is a marketed brand name for tadalafil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tadalafil?
tadalafil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.